TREATMENT OF SICKLE CELL PAIN Marlowe and Chicella
491
disease. N Engl J Med 1991;325:11–16.
crisis. Pediatrics 1994;93:310–15.
4. Davis H, Moore R, Gergen P. Cost of hospitalizations
associated with sickle cell disease in the United States. Public
Health Rep 1997;112:40–3.
32. Trentadue N, Kachoyeanos M, Lea G. A comparison of two
regimens of patient-controlled analgesia for children with sickle
cell disease. J Pediatr Nurs 1998;13:15–19.
5. Elander J, Midence K. A review of evidence about factors
affecting quality of pain management in sickle cell disease. Clin
J Pain 1996;12:180–93.
6. Yale S, Nagib N, Guthrie T. Approach to the vaso-occlusive
crisis in adults with sickle cell disease. Am Fam Physician
2000;61:1349–56.
33. Robieux IC, Kellner JD, Coppes MJ, et al. Analgesia in
children with sickle cell crisis: comparison of intermittent opioids
vs. continuous infusion morphine and placebo controlled study of
oxygen inhalation. Pediatr Hematol Oncol 1992;9:317–26.
34. Brookhoff D, Polomano R. Treating sickle cell pain like cancer
pain. Ann Intern Med 1992;116:364–8.
7. Beyer J. Judging the effectiveness of analgesia for children and
adolescents during vaso-occlusive events of sickle cell disease. J
Pain Symptom Manage 2000;19:63–72.
8. Anonymous. JCAHO begins surveying for new pain standards.
Hosp Peer Rev 2000;25(5):67–8.
35. Gonzalez E, Ornato J, Ware D, Bull D, Evens RP. Comparison
of intramuscular analgesic activity of butorphanol and
morphine in patients with sickle cell disease. Ann Emerg Med
1988;17:788–91.
36. Dampier C, Setty B, Logan J, Loli J, Dean R. Intravenous
morphine pharmacokinetics in pediatric patients with sickle
cell disease. J Pediatr 1995;126:461–7.
9. Platt O. Easing the suffering caused by sickle cell disease. N
Engl J Med 1994;330:783–4.
10. Schulman E, Natarajan M. Pathophysiology and management
of sickle cell pain crisis: report of a meeting of physicians and
scientists. Lancet 1995;346:1408–12.
37. Abbuhl S, Jacobson S, Murphy J. Serum concentrations of
meperidine in patients with sickle cell crisis. Ann Emerg Med
1986;15:433–8.
11. Steinberg M. Drug therapy: management of sickle cell disease.
N Engl J Med 1999;340:1021–30.
12. Serjeant G. Sickle-cell disease. Lancet 1997;350:725–30.
13. Beyer J, Platt A, Kinney T, Treadwell M. Practice guidelines for
the assessment of children with sickle cell pain. J Soc Pediatr
Nurses 1999;4:61–73.
14. Vijay V, Cavenagh P, Yate P. The anaesthetist’s role in acute
sickle cell crisis. Br J Anaesth 1998;80:820–8.
15. Beyer J, Simmons L, Woods G, Woods P. A chronology of pain
and comfort in children with sickle cell disease. Arch Pediatr
Adolesc Med 1999;153:913–20.
38. Woods G, Parson P, Strickland D. Efficacy of nalbuphine as a
parenteral analgesic for the treatment of painful episodes in
children with sickle cell disease. J Assoc Acad Minor Phys
1990;1:90–2.
39. Richardson P, Steingart R. Meperidine and ketorolac in the
treatment of painful sickle cell crisis. Ann Emerg Med
1993;22:1639–40.
40. Goodman E. Use of ketorolac in sickle cell disease and vaso-
occlusive crisis. Lancet 1991;338:641–2.
41. Wright SW, Norris RL, Mitchell TR. Ketorolac for sickle cell
vaso-occlusive crisis pain in the emergency department: lack of
a narcotic sparing effect. Ann Emerg Med 1992;21:925–8.
42. Hardwick W, Givens T, Monroe K, King W, Lawley D. Effect of
ketorolac in pediatric sickle cell vaso-occlusive pain crisis.
Pediatr Emerg Care 1999;15:179–82.
43. Beiter J, Simon H, Chambliss C, Adamkiewicz T, Sullivan K.
Intravenous ketorolac in the emergency department
management of sickle cell pain and predictors of its
effectiveness. Arch Pediatr Adolesc Med 2001;155:496–500.
44. Eke F, Obamyonyi A, Eke N, Oyewa E. An open comparative
study of dispersible piroxicam versus soluble acetylsalicylic
acid for the treatment of osteoarticular painful attack during
sickle cell crisis. Trop Med Int Health 2000;5:81–4.
16. Ballas S. The sickle cell painful crisis in adults: phases and
objective signs. Hemoglobin 1995;19:323–33.
17. Sanders D, Severance H, Pollack C. Sickle cell vaso-occlusive
pain crisis in adults: alternative strategies for management in
the emergency department. South Med J 1992;85:808–11.
18. Waldrop R, Mandry C. Health professionals’ perceptions of
opioid dependence among patients with pain. Am J Emerg Med
1995;13:529–31.
19. Cole T, Sprinkle R, Smith S, Buchanan G. Intravenous
narcotic therapy for children with severe sickle cell pain crisis.
Am J Dis Child 1986;140:1255–9.
20. Gorman K. Sickle cell disease. Am J Nurs 1999;99:38–43.
21. Ballas S. Treatment of pain in adults with sickle cell disease.
Am J Hematol 1990;34:49–54.
22. Murray N, May A. Painful crises in sickle cell disease: patient’s
perspective. BMJ 1988;297:452–4.
45. Griffin T, McIntire D, Buchanan G. High-dose intravenous
methylprednisolone therapy for pain in children and
adolescents with sickle cell disease. N Engl J Med 1994;330:
733–7.
23. Burghardt-Fitzgerald D. Pain-behavior contracts: effective
management of the adolescent in sickle-cell crisis. J Pediatr
Nurs 1989;4:320–4.
46. Ballas S. Complications of sickle cell anemia in adults:
guidelines for effective management. Cleve Clin J Med
1999;66:48–58.
24. Sporrer K, Jackson S, Agner S, et al. Pain in children and
adolescents with sickle cell anemia: a prospective study uti-
lizing self-reporting. Am J Pediatr Hematol Oncol 1994;16:219–24.
25. Sutton M, Atweh G, Cashman T, Davis W. Resolving conflicts:
misconceptions and myths in the care of the patient with sickle
cell disease. Mt Sinai J Med 1999;66:282–5.
26. Benjamin L, Swinson G, Nagel R. Sickle cell anemia day
hospital: an approach for management of uncomplicated
painful crisis. Blood 2000;95:1130–6.
27. Pegelow C. Survey of pain management therapy provided for
children with sickle cell disease. Clin Pediatr 1992;31:211–14.
28. Gonzalez E, Bahal N, Hansen L, et al. Intermittent injection vs
patient-controlled analgesia for sickle cell crisis pain. Arch
Intern Med 1991;151:1373–8.
47. Gil K, Carson J, Sedway J, Porter L, Schaeffer J, Orringer E.
Follow-up of coping skills training in adults with sickle cell
disease: analysis of daily pain and coping practice diaries.
Health Psych 2000;19:85–90.
48. Charache S, Terrin M, Morre R, et al. Effect of hydroxyurea on
the frequency of painful crises in sickle cell anemia. N Engl J
Med 1995;332:1317–22.
49. Koren A, Segal-Kupershmit D, Zalman L, et al. Effect of
hydroxyurea in sickle cell anemia: a clinical trial in children
and teenagers with severe sickle cell anemia and sickle cell
beta-thalassemia. Pediatr Hematol Oncol 1999;16:221–32.
50. Kinney T, Helms R, O’Branski E, et al. Safety of hydroxyurea
in children with sickle cell anemia: results of the HUG-KIDS
study. Blood 1999;94:1550–4.
29. Jacobson S, Kopecky E, Prashant J, Babul N. Randomised trial
of oral morphine for painful episodes of sickle-cell disease in
children. Lancet 1997;350:1358–61.
30. Conti C, Tso E, Browne B. Oral morphine protocol for sickle
cell crisis pain. Md Med J 1996;45:33–5.
51. Michaels L, Oheme-Frempona K, Zhao H, Douglas S. Serum
levels of substance P are elevated in patients with sickle cell
disease and increase further during vaso-occlusive crisis. Blood
1998;92:3148–51.
52. CytRx Corporation. Flocor granted “fast track” status by FDA
for treatment of acute chest syndrome in sickle cell disease
[press release]. Atlanta, GA: CytRx Corporation; June 14, 2001.
31. Yaster M, Tobin J, Billett C, Casella J, Dover G. Epidural
analgesia in the management of severe vaso-occlusive sickle cell